Quince Therapeutics (NASDAQ:IRLA – Get Free Report) had its price objective boosted by equities research analysts at Citizens Jmp from $77.00 to $86.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp‘s price target would indicate a potential upside of 116.08% from the company’s previous close.
A number of other analysts have also issued reports on the company. Weiss Ratings initiated coverage on Quince Therapeutics in a research note on Tuesday, October 13th. They issued a “sell (d-)” rating on the stock. Raymond James Financial raised shares of Quince Therapeutics to a “moderate buy” rating in a research note on Friday, October 9th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Quince Therapeutics currently has an average rating of “Hold” and a consensus target price of $86.00.
Read Our Latest Stock Report on IRLA
Quince Therapeutics Price Performance
Quince Therapeutics stock opened at $39.80 on Monday. Quince Therapeutics has a 52 week low of $15.10 and a 52 week high of $909.98. The firm has a market capitalization of $40.60 million, a P/E ratio of -0.37 and a beta of 1.78.
Quince Therapeutics Company Profile
Quince Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure. Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release.
Further Reading
- Five stocks we like better than Quince Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
